Neurotrack Raises $6.5M in Funding

Neurotrack_logoNeurotrack, a Palo Alto, CA-based provider of a digital cognitive assessment, raised $6.5m in funding.

The round was led by Khosla Ventures with participation from Social Capital, Founders Fund, AME Cloud Ventures and iSeed Ventures.

The company, which has raised $9.5m to date, intends to use the funds to accelerate research, product development, and recruiting.

Led by Elli Kaplan, CEO and co-founder, Neurotrack has just announced the release of its first product, Imprint™, a digital cognitive assessment test that will enable earlier and more effective evaluation of patients who may be at risk for cognitive decline and help advance research and treatment of cognitive diseases like Alzheimer’s. Built on research led by Neurotrack co-founder Dr. Stuart Zola, Imprint™ is a 5-minute web-based test that utilizes eye tracking technology to assess recognition memory and hippocampal impairment.

The test is currently being used by research institutions with more than 3,000 people in Alzheimer’s studies as well as in pharmaceutical trials for the development of treatments for Alzheimer’s disease. Institutions include Brown University, Emory University’s Alzheimer’s Disease Research Center, Harvard University, NYU Langone Medical Center, the Shanghai Mental Health Center and Stanford University.

It will become available through select physicians in 2016.

In addition to the test, the company has also launched the private beta of a cognitive health product, a personalized lifestyle program that brings together scientific research to reduce the risk of cognitive decline and improve overall cognitive health. It represents a multipart intervention, built on lifestyle recommendations in diet, exercise, cognitive training, sleep and stress management that have been shown to prevent decline and improve cognitive scores in people at risk for impairment. The product is based on pivotal research in nutrition by Dr. Martha Clare Morris, based at Rush University Medical Center and Dr. Miia Kivipelto, an Alzheimer’s expert and Karolinska Institute professor who led the landmark Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER).

Beyond Kaplan, and Dr. Stuart Zola, Ph.D., co-founders in the company include Dr. Elizabeth Buffalo, Ph.D. and Cecelia Manzanares.



Join the discussion